Table 1.
Revue of literature of outcome of combine therapy compared to AmB monotherapy in the treatment of mucormycosis.
| Series | Country of study | Year of study | Number of cases | Type of study | Pathological history | Age at Diagnosis (years) | Cause of Combine therapy | Combine Therapy and duration (days) | Outcome of Combine therapy |
|---|---|---|---|---|---|---|---|---|---|
| Kocoglu [14] | Turkey | 2017 | 1 | Humain | Diabetes | 51/F | Progression of the disease | Liposomal AmphotericinB + Caspofungin | Clinical success |
| Sheybani [2] | Iran | 2015 | 2 | Humain | Diabetes | 64/F 43/H |
Adverse reaction to AMB | Posaconazol + Caspofungin (30 days/42 days) | Clinical success |
| Abidi [15] | USA | 2014 | 101 | Humain | •Oncologic Malignancy •Organ or stem cell transplantation |
52/M | Severe cases | Liposomal AmphotericinB+ Caspofungin And/or posaconazole |
combination anti-fungal therapy has not improved survival |
| Kazak [9] | Turkey | 2013 | 1 | Humain | Diabetes | 41/F | Progression of the disease | Liposomal AmphotericinB+ Caspofungin (62 days) |
Regression of clinical and radiological condition |
| Lanterier [16] | France | 2012 | 101 | Humain | •Hematological malignancies (50%) •diabetes (23%) •trauma (18%) |
50/H | patients with hematological malignancies |
Liposomal AmphotericinB+ Posaconazole Or Liposomal AmphotericinB+ Caspofungin Or Liposomal AmphotericinB+ Caspofungin+ Posaconazole |
combination anti-fungal therapy has not improved survival |
| Ibrahim [17] | USA | 2012 | Murin | Diabetes neutropenia | Liposomal AmphotericinB+ Posaconazole |
• Benefit of combination therapy during intranasal or inhalational zygomycosis. •The study do not support combination polyene-posaconazole therapy for disseminated zygomycosis. |
|||
| Ojeda [10] | Paris | 2010 | 1 | Humain | •acute myeloid leukaemia •Diabetes |
55/F | Neutropenic Patientsduring The Induction of chemotherapy |
Liposomal AmphotericinB+ Caspofungin (56 days) |
Clinical success |
| Reed [13] | LA, USA | 2008 | 41 | Humain | •Diabetes (83%) •cancer (34%) •corticosteroid therapy (46%) •neutropenia (12%) •transplantation (10%) |
51/24 M (4–83) | Liposomal AmphotericinB+ Caspofungin |
•Therapeutic success •survival benefit most pronounced with patients with cerebral involvement |
|
| Vaquez [11] | Spain | 2005 | 1 | Humain | acute myelogenous leukaemia |
63/M | Progression of the disease | Liposomal AmphotericinB+ Caspofungin (45 days) |
Clinical success |
| Spellberg [18] | LA, USA | 2004 | Murine | Liposomal AmphotericinB+ Caspofungin (4 days) |
•Survival benefit •Prophylactic combine therapy was not more effective than prophylactic ABLC alone |
||||
| Our study | Tunisia | 2018 | 1 | Humain | Diabetes | 52/F | Progression of the disease | AmphotericinB+ Caspofungin (32 days) |
Regression of clinical and radiological condition |